Synergistic Hepatic Disease Treatment Platform
Legal Citation
Summary of the Inventive Concept
A novel system integrating toll-like receptor (TLR) ligands with advanced technologies such as AI, IoT, blockchain, and nanomaterials to provide personalized, data-driven treatment of hepatic diseases and disorders.
Background and Problem Solved
The original patent disclosed compositions and methods for treating hepatic diseases using TLR ligands. However, the treatment outcomes were limited by the lack of personalized approach and inefficient data management. The new inventive concept addresses these limitations by combining TLR ligands with cutting-edge technologies to create a more effective and targeted treatment platform.
Detailed Description of the Inventive Concept
The Synergistic Hepatic Disease Treatment Platform consists of a pharmaceutical composition incorporating a TLR ligand, an AI module for optimizing the composition's therapeutic efficacy based on patient-specific genomic data, and a blockchain-based data management system for secure storage and tracking of patient treatment data. Additionally, the platform may utilize IoT sensors for monitoring patient health metrics and machine learning algorithms for analyzing the sensor data and providing personalized treatment recommendations. The system may also incorporate nanomaterial-based delivery systems and 3D printing technology for synthesizing novel pharmaceutical compositions.
Novelty and Inventive Step
The new inventive concept introduces the synergistic combination of TLR ligands with AI, IoT, blockchain, and nanomaterials, which is not obvious from the original patent. The integration of these technologies provides a novel and non-obvious solution for personalized treatment of hepatic diseases and disorders.
Alternative Embodiments and Variations
Alternative embodiments of the platform may include the use of different AI algorithms, IoT sensor configurations, or blockchain protocols. Variations of the platform may also incorporate other advanced technologies, such as gene editing or synthetic biology, to further enhance its therapeutic efficacy.
Potential Commercial Applications and Market
The Synergistic Hepatic Disease Treatment Platform has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of hepatitis and liver fibrosis. The platform's ability to provide personalized and data-driven treatment approaches may lead to improved treatment outcomes and reduced healthcare costs.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology with a focus on immunomodulatory treatments for hepatic diseases, involving expertise in immunology, drug formulation, and therapeutic composition design
Person of Ordinary Skill (PHOSITA) Profile
A researcher or pharmaceutical scientist with advanced degrees in biotechnology or pharmacology, familiar with toll-like receptor (TLR) ligand technologies, immunomodulatory drug development, and emerging digital health technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies with existing pharmaceutical compositions represents a predictable extension of standard drug development practices. The combination of TLR-based treatments with AI, blockchain, and IoT monitoring represents an obvious technological convergence in personalized medicine. The PTD's variations merely apply known digital technologies to an existing pharmaceutical approach in a manner that would be readily conceived by a skilled practitioner.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,577 |
|---|---|
| Title | Compositions and methods for the treatment of hepatic diseases and disorders |
| Assignee(s) | Labyrinth Holdings, LLC |